

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 26 OCTOBER 2022

Reference is made to the circular (the “**Circular**”) and the notice of extraordinary general meeting (the “**Notice**”) dated 6 October 2022 of SinoMab BioScience Limited (the “**Company**”). Unless the content otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EGM

At the EGM, all the proposed resolutions as set out in the Notice were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	“THAT, subject to and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) granting approval for the listing of, and permission to deal in, the shares of the Company (“ Shares ”) which may fall to be issued and allotted pursuant to the exercise of any options which may be granted under the new share option scheme of the Company (the “ 2022 Share Option Scheme ”), the rules of which are contained in the document marked “A” produced to this meeting and signed by the chairman of this meeting for	540,951,813 (100%)	0 (0%)

Ordinary Resolutions	Number of Votes (%)	
	For	Against
<p>identification purpose, the 2022 Share Option Scheme and the scheme mandate limit of 50,312,020 Shares be and is hereby approved and adopted and the directors of the Company be and are hereby authorised to take all such steps and attend all such matters, approve and execute (whether under hand or under seal) such documents and do such other things, for and on behalf of the Company, as the directors of the Company may consider necessary, desirable or expedient to effect and implement the 2022 Share Option Scheme, including without limitation,</p> <p>a. administering the 2022 Share Option Scheme under which options will be granted to participants eligible under the 2022 Share Option Scheme to subscribe for Shares;</p> <p>b. modifying and/or amending the 2022 Share Option Scheme from time to time provided that such modification and/or amendment is effected in accordance with the provisions of the 2022 Share Option Scheme relating to modification and/or amendment and the requirements of the Rules Governing the Listing of Securities on the Stock Exchange (“Listing Rules”);</p> <p>c. granting options to subscribe for Shares under the 2022 Share Option Scheme and allotting and issuing from time to time such number of Shares as may be required to be issued pursuant to the exercise of the options that may be granted under the 2022 Share Option Scheme and subject to the Listing Rules;</p>		

Ordinary Resolutions		Number of Votes (%)	
		For	Against
	<p>d. making application at the appropriate time or times to the Stock Exchange, and any other stock exchanges upon which the issued shares of the Company may for the time being be listed, for the listing of, and permission to deal in, any new shares of the Company or any part thereof that may hereafter from time to time be allotted and issued pursuant to the exercise of the options granted under the 2022 Share Option Scheme; and</p> <p>e. consenting, if it so deems fit and expedient, to such conditions, modifications and/or variations as may be required or imposed by the relevant authorities in relation to the 2022 Share Option Scheme.”</p>		
2.	<p>As special business, to consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:</p> <p>“THAT, the Service Provider Sublimit (as defined in the 2022 Share Option Scheme) on the total number of Shares that may be issued in respect of all options and awards to be granted to service providers under all the share schemes of the Company be and is hereby approved and adopted and the directors of the Company be and are hereby authorised to take all such steps and attend all such matters, approve and execute (whether under hand or under seal) such documents and do such other things, for and on behalf of the Company, as the directors of the Company may consider necessary, desirable or expedient to effect and implement the Service Provider Sublimit.”</p>	540,951,813 (100%)	0 (0%)

Notes:

- (a) As all of the votes were cast in favour of each of the resolutions numbered 1 to 2, all resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the EGM, the total number of shares of the Company in issue was 1,006,240,400 shares.
- (c) The total number of shares of the Company entitling the holders to attend and vote on all the resolutions at the EGM was 1,006,240,400 shares.
- (d) There were no shares entitling the holders to attend and abstain from voting in favour of any of the resolutions at the EGM as set out in rule 13.40 of the Listing Rules.
- (e) None of the shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions at the EGM.
- (f) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.
- (g) The Company's share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the poll taken at the EGM.
- (h) The following directors of the Company, namely Dr. Shui On LEUNG, Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU, Mr. Lei SHI, Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho HON and Dr. Chi Ming LEE attended the EGM either in person or by electronic means. Mr. Dylan Carlo TINKER was unable to attend the EGM due to other business commitments.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 26 October 2022

As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.